Hae-Ock Lee

Prof. Hae-Ock Lee

College of Medicine, The Catholic University of Korea, Seoul, Korea
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
NKNayoung Kim
Nayoung Kim
HKHong Kwan Kim
Hong Kwan Kim
Kyungjong LeeKyungjong Lee
Kyungjong Lee
YHYourae Hong
Yourae Hong
JCJong Ho Cho
Jong Ho Cho
Hae-Ock LeeHae-Ock Lee
Hae-Ock Lee
Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell transcriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions.

25 May 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
Hae-Ock LeeHae-Ock Lee
Hae-Ock Lee
YHYourae Hong
Yourae Hong
HEHakki Emre Etlioglu
Hakki Emre Etlioglu
YCYong Beom Cho
Yong Beom Cho
VPValentina Pomella
Valentina Pomella
WPWoong-Yang Park
Woong-Yang Park

19 June 2015 in Genome Biology
Verified
Journal Article
Open access
PDF file
KKKyu-Tae Kim
Kyu-Tae Kim
HLHye Won Lee
Hye Won Lee
Hae-Ock LeeHae-Ock Lee
Hae-Ock Lee
SKSang Cheol Kim
Sang Cheol Kim
YSYun Jee Seo
Yun Jee Seo
WPWoong-Yang Park
Woong-Yang Park
Background: Intra-tumoral genetic and functional heterogeneity correlates with cancer clinical prognoses. However, the mechanisms by which intra-tumoral heterogeneity impacts therapeutic outcome remain poorly understood. RNA sequencing (RNA-seq) of single tumor cells can provide comprehensive information about gene expression and single-nucleotide variations in individual tumor cells, which may allow for the translation of heterogeneous tumor cell functional responses into customized anti-cancer treatments. Results: We isolated 34 patient-derived xenograft (PDX) tumor cells from a lung adenocarcinoma patient tumor xenograft. Individual tumor cells were subjected to single cell RNA-seq for gene expression profiling and expressed mutation profiling. Fifty tumor-specific single-nucleotide variations, including KRAS G12D , were observed to be heterogeneous in individual PDX cells. Semi-supervised clustering, based on KRAS G12D mutant expression and a risk score representing expression of 69 lung adenocarcinoma-prognostic genes, classified PDX cells into four groups. PDX cells that survived in vitro anti-cancer drug treatment displayed transcriptome signatures consistent with the group characterized by KRAS G12D and low risk score. Conclusions: Single-cell RNA-seq on viable PDX cells identified a candidate tumor cell subgroup associated with anti-cancer drug resistance. Thus, single-cell RNA-seq is a powerful approach for identifying unique tumor cell-specific gene expression profiles which could facilitate the development of optimized clinical anti-cancer strategies.

29 April 2016 in Genome Biology
Verified
Journal Article
Open access
PDF file
KKKyu-Tae Kim
Kyu-Tae Kim
HLHye Won Lee
Hye Won Lee
Hae-Ock LeeHae-Ock Lee
Hae-Ock Lee
HSHye Jin Song
Hye Jin Song
DJDa Eun Jeong
Da Eun Jeong
WPWoong-Yang Park
Woong-Yang Park
Intratumoral heterogeneity hampers the success of marker-based anticancer treatment because the targeted therapy may eliminate a specific subpopulation of tumor cells while leaving others unharmed. Accordingly, a rational strategy minimizing survival of the drug-resistant subpopulation is essential to achieve long-term therapeutic efficacy. Using single-cell RNA sequencing (RNA-seq), we examine the intratumoral heterogeneity of a pair of primary renal cell carcinoma and its lung metastasis. Activation of drug target pathways demonstrates considerable variability between the primary and metastatic sites, as well as among individual cancer cells within each site. Based on the prediction of multiple drug target pathway activation, we derive a combinatorial regimen co-targeting two mutually exclusive pathways for the metastatic cancer cells. This combinatorial strategy shows significant increase in the treatment efficacy over monotherapy in the experimental validation using patient-derived xenograft platforms in vitro and in vivo. Our findings demonstrate the investigational application of single-cell RNA-seq in the design of an anticancer regimen. The approach may overcome intratumoral heterogeneity which hampers the success of precision medicine.

15 January 2023 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
NKNayoung Kim
Nayoung Kim
HKHuiram Kang
Huiram Kang
AJAreum Jo
Areum Jo
SYSeung-Ah Yoo
Seung-Ah Yoo
Hae-Ock LeeHae-Ock Lee
Hae-Ock Lee
Single-cell RNA sequencing has become a powerful and essential tool for delineating cellular diversity in normal tissues and alterations in disease states. For certain cell types and conditions, there are difficulties in isolating intact cells for transcriptome profiling due to their fragility, large size, tight interconnections, and other factors. Single-nucleus RNA sequencing (snRNA-seq) is an alternative or complementary approach for cells that are difficult to isolate. In this review, we will provide an overview of the experimental and analysis steps of snRNA-seq to understand the methods and characteristics of general and tissue-specific snRNA-seq data. Knowing the advantages and limitations of snRNA-seq will increase its use and improve the biological interpretation of the data generated using this technique.

4 December 2020 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
HEHye Hyeon Eum
Hye Hyeon Eum
MKMinsuk Kwon
Minsuk Kwon
DRDaeun Ryu
Daeun Ryu
AJAreum Jo
Areum Jo
WCWoosung Chung
Woosung Chung
WPWoong-Yang Park
Woong-Yang Park
Gastric cancer (GC) patients develop malignant ascites as the disease progresses owing to peritoneal metastasis. GC patients with malignant ascites have a rapidly deteriorating clinical course with short survival following the onset of malignant ascites. Better optimized treatment strategies for this subset of patients are needed. To define the cellular characteristics of malignant ascites of GC, we used single-cell RNA sequencing to characterize tumor cells and tumor-associated macrophages (TAMs) from four samples of malignant ascites and one sample of cerebrospinal fluid. Reference transcriptomes for M1 and M2 macrophages were generated by in vitro differentiation of healthy blood-derived monocytes and applied to assess the inflammatory properties of TAMs. We analyzed 180 cells, including tumor cells, macrophages, and mesothelial cells. Dynamic exchange of tumor-promoting signals, including the CCL3–CCR1 or IL1B–IL1R2 interactions, suggests macrophage recruitment and anti-inflammatory tuning by tumor cells. By comparing these data with reference transcriptomes for M1-type and M2-type macrophages, we found noninflammatory characteristics in macrophages recovered from the malignant ascites of GC. Using public datasets, we demonstrated that the single-cell transcriptome-driven M2-specific signature was associated with poor prognosis in GC. Our data indicate that the anti-inflammatory characteristics of TAMs are controlled by tumor cells and present implications for treatment strategies for GC patients in which combination treatment targeting cancer cells and macrophages may have a reciprocal synergistic effect.